Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Blockbuster win for Novartis

Posted 14 October 2020

The patent on an oral form of the Novartis blockbuster multiple sclerosis drug Gilenya has been given the go ahead to proceed to grant after a ruling in the Federal Court ended a three year legal stoush with generic giant Arrow Pharmaceuticals.

"Novartis welcomes the decision by Justice Burley that the appeal be allowed and the patent application proceed to grant," the company said in a statement.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pharma face-slapped for success
Reputation is finding itself under threat again
Approvals Action
Low dose Symdeko ticked
Along with one generic drug
Special Report
March 2021 PBAC outcomes
Less than a quarter of major new listing requests recommended